Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Kommende kliniske studier
-
Seoul National University HospitalSamil Pharmaceutical Co., Ltd.RekrutteringSarkopeni | Total kneartroplastikkSør -Korea
-
Stanford UniversityHar ikke rekruttert ennåAkutt myeloid leukemi | Myelodysplastiske syndromer | Myeloproliferativ neoplasmaForente stater
-
Cheng QiRekruttering
-
Stanford UniversityHar ikke rekruttert ennåLeversviktForente stater
-
Istanbul Aydın UniversityHar ikke rekruttert ennåNakkesmerter | Myofascial smertesyndrom | Arbeidsrelaterte muskel- og skjelettlidelserTyrkia (Türkiye)
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Har ikke rekruttert ennåTilbakevendende endometriekarsinom | Avansert endometriekarsinom | Metastatisk endometriekarsinom | Stadium III endometrial kreft | Stadium IV Endometrial kreftForente stater
-
University of Colorado, DenverRekrutteringUngdoms idiopatisk skoliose (AIS) | Nevromuskulær skolioseForente stater
-
University of FloridaAmerican Heart AssociationRekrutteringHjertesvikt med bevart ejeksjonsfraksjon (HFPEF)Forente stater
-
UNC Lineberger Comprehensive Cancer CenterHar ikke rekruttert ennåLeukemi | Akutt lymfatisk leukemi | Lymfoblastisk lymfom | Akutt leukemi | Akutt lymfoid leukemiForente stater
-
Korea University Anam HospitalThe Catholic University of Korea; Keimyung University Dongsan Medical Center og andre samarbeidspartnereHar ikke rekruttert ennåUrologisk kreft | Myokardskade etter ikke-hjertekirurgi | Store bivirkninger
-
Montefiore Medical CenterHar ikke rekruttert ennåCesarean Scar Defect (Isthmocele)Forente stater
-
SanofiHar ikke rekruttert ennå
Clinical Research Jobs
-
Philippines - Manila
-
Taiwan - Taipei
-
United States - Shrewsbury
-
Germany - Munich
-
Germany - Nordrhein-Westfalen - CologneAustria
-
Serbia - Belgrade
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China
